The Daiichi Sankyo Group is promoting partnership-based drug discovery to make the best use of its accumulated scientific findings and global network. Partnerships bring synergies to initiatives that cannot be completed by the Group alone. This initiative contributes to Goal 17: “Partnerships for the Goals” of the Sustainable Development Goals (SDGs) adopted by the United Nations member states.
The Daiichi Sankyo Group has funded the Global Health Innovative Technology Fund (hereinafter referred to as the “GHIT Fund”) since its establishment in April 2013. To promote the development of drugs for combating infectious diseases in developing countries, the GHIT Fund was established as a public-private partnership originating in Japan and was supported by the government of Japan, five Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation. We have continued the funding for the second phase starting in April 2018. The GHIT Fund has contributed to breakthroughs in many innovative product developments through its investments.
The Group is utilizing the partnership through the GHIT Fund structure to undertake a number of projects, including one to explore clinical candidate compounds for the treatment of Chagas disease, which is considered to be a neglected tropical disease (NTD), and another to explore candidate anti-tuberculosis drugs from natural products. In these projects, we are integrating our accumulated drug discovery capabilities, our partners’ expertise in diseases, and the GHIT Fund’s investment capabilities and its global network.
Daiichi Sankyo will continue with activities that contribute to fulfilling its corporate mission through initiatives to create innovative pharmaceuticals and improve medical access in developing countries.
The Global Health Innovative Technology Fund
VOICE Quest to Create Global Health Benefits that Are Recognized Both Inside and Outside of Daiichi Sankyo
Sustainability Promotion Department,
Corporate Affairs Division,
Daiichi Sankyo Co., Ltd.
Since the GHIT Fund was established in 2013, the Daiichi Sankyo Group has been taking part in its project for exploring treatments related to global health. In this project, we began with screening the Company’s unique compounds and then moved on to research in a phased manner, and we are currently engaged in exploratory research on treatments for malaria, tuberculosis, and the neglected tropical diseases (leishmaniasis and Chagas disease). Research in all of these areas is still in the initial phases. Those of us on the Daiichi Sankyo Group’s research team are working together with research partners as we forge ahead with research with the aim of fully utilizing the Group’s drug discovery expertise to save patients. These efforts are still relatively unknown outside of the Company. For this reason, I see it as my quest to create results that are recognized both inside and outside of the Company as an indication of Daiichi Sankyo’s dedicated efforts to aid various stakeholders around the world.